Business Description
Whitehawk Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00032Q1040
Total Employee Number:
23Description
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.91 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -44.6 | |||||
3-Year EBITDA Growth Rate | 50.1 | |||||
3-Year EPS without NRI Growth Rate | 11.7 | |||||
3-Year FCF Growth Rate | 10.7 | |||||
3-Year Book Growth Rate | -23.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -45.59 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.89 | |||||
9-Day RSI | 41.42 | |||||
14-Day RSI | 44.25 | |||||
3-1 Month Momentum % | 21.13 | |||||
6-1 Month Momentum % | 53.57 | |||||
12-1 Month Momentum % | 105.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.36 | |||||
Quick Ratio | 11.36 | |||||
Cash Ratio | 11.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -1523.19 | |||||
OCF Margin % | -1523.17 | |||||
ROE % | -72.07 | |||||
ROA % | -67.34 | |||||
ROIC % | -3714.93 | |||||
3-Year ROIIC % | 1089.68 | |||||
ROC (Joel Greenblatt) % | -1362023.26 | |||||
ROCE % | -72.89 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 8.1 | |||||
PS Ratio | 34.61 | |||||
PB Ratio | 1.62 | |||||
Price-to-Tangible-Book | 1.62 | |||||
EV-to-EBIT | -0.44 | |||||
EV-to-EBITDA | -0.44 | |||||
EV-to-Revenue | 7.16 | |||||
EV-to-FCF | -0.47 | |||||
Price-to-GF-Value | 14.42 | |||||
| Price-to-Net-Current-Asset-Value | 1.64 | |||||
| Price-to-Net-Cash | 1.68 | |||||
Earnings Yield (Greenblatt) % | -227.27 | |||||
FCF Yield % | -54.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Whitehawk Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.102 | ||
| EPS (TTM) (€) | -1.448 | ||
| Beta | 0.0446 | ||
| 3-Year Sharpe Ratio | 0.14 | ||
| 3-Year Sortino Ratio | 0.2 | ||
| Volatility % | 41.07 | ||
| 14-Day RSI | 44.25 | ||
| 14-Day ATR (€) | 0.239221 | ||
| 20-Day SMA (€) | 3.675 | ||
| 12-1 Month Momentum % | 105.99 | ||
| 52-Week Range (€) | 1.33 - 4.44 | ||
| Shares Outstanding (Mil) | 49.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Whitehawk Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Whitehawk Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 117 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 26 days | ||
| General meeting for 2026 | 2026-06-11 13:00 | 3.44 (-3.37%) | ||
| Guidance call for 2026 | 2026-06-04 08:10 | 3.70 (+5.11%) | ||
| TD Cowen 7th Annual Oncology Innovation | 2026-05-27 11:00 | 4.04 (+5.76%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.52 (+0.00%) | ||
| Jones Trading Post-AACR Fireside Chat Series | 2026-04-23 15:00 | 3.56 (+1.14%) | ||
| Annual report for 2025 | 2026-03-12 | 3.40 (+0.59%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 3.40 (+0.59%) | ||
| Citizens Life Sciences Conference | 2026-03-10 12:30 | 3.52 (+12.10%) |
Show
Entries
Whitehawk Therapeutics Inc Frequently Asked Questions
What is Whitehawk Therapeutics Inc(STU:3350)'s stock price today?
The current price of STU:3350 is €3.46. The 52 week high of STU:3350 is €4.44 and 52 week low is €1.33.
When is next earnings date of Whitehawk Therapeutics Inc(STU:3350)?
The next earnings date of Whitehawk Therapeutics Inc(STU:3350) is 2026-08-07 Est..
Does Whitehawk Therapeutics Inc(STU:3350) pay dividends? If so, how much?
Whitehawk Therapeutics Inc(STU:3350) does not pay dividend.
Press Release
Articles on Whitehawk Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers